Determine the Safest Course of Radiation Treatment for Your Prostate Cancer Patients
Localized prostate cancer has an excellent prognosis, with a five-year survival rate of over 99%.1 While radiotherapy is an effective treatment, more than 20% of men experience late side effects that start three to six months after therapy, which can negatively impact their quality of life.2 Choosing the right treatment option is important to ensure a future where the highest quality of life is not only a possibility but the likely outcome from cancer treatment.
PROSTOX Ultra
For patients considering SBRT
PROSTOX Standard
For patients considering CFRT or MHFRT
PROSTOX testing is designed to help support treatment decisions with your prostate cancer patients.
Using unique inherited microRNA-based genetic biomarker panels, these tests identify patients at HIGH or LOW-AVERAGE risk of late genitourinary (GU) adverse events from either SBRT or CFRT/MHFRT, before treatment starts.
Know your Patient’s Risk
Identifying if one treatment is safer than another helps to select the best treatment approach. Ordering physicians can choose either PROSTOX Ultra for SBRT or PROSTOX Standard for CFRT/MHFRT, or both tests using a single buccal swab.
Most patients will be LOW-AVERAGE RISK to both treatments (72%), while some will be high risk to either SBRT (13%) or CFRT/MHFRT (11%). In rare cases, a patient may be at HIGH RISK for both SBRT and CFRT/MHFRT (4%).3
When we initially reported PROSTOX Ultra and PROSTOX Standard over four years ago, a common question we received was whether these tests had been validated in a larger scale cohort. This further persisted when we reported the results of the MIRAGE trial, which showed a reduction in adverse events with the use of modern technology to achieve high precision in stereotactic body radiotherapy (SBRT), particularly with MRI-guidance. Our most recent analysis provides strong independent validation of both PROSTOX Ultra and PROSTOX Standard as robust predictors of adverse events after modern radiotherapy across multiple patient cohorts. With these results, I feel confident in discussing fractionation-specific risk with patients I see in consultation so that they can make informed decisions to optimize their quality of life.”
Dr. Amar Kishan, MD, Radiation Oncologist
Executive Vice Chair for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center
PROSTOX
References:
- LitwanMS, Tan HJ. The diagnosis and treatment of prostate cancer--a review. JAMA. 2017;317(24):2532-2542. doi:10.1001/jama.2017.7248.
- Van As N, Griffin C, Tree AC, et al. et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. New Engl J Med. 2024;391:1413-1425. DOI: 10.1056/NEJMoa2403365.
- Based on internal data from patients in clinical trials and real-world clinical settings.